Clinical trials
Prostate cancer clinical trials
Cancer of the prostate gland, one of the most common cancers in men. We’re tracking 1,215 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07689656RecruitingPhase 1/Phase 2
PET imaging study for prostate cancer using a new tracer
This trial tests a new radioactive tracer called ELI421 to see how well it works for PET imaging in people with prostate cancer. It may help doctors find cancer more clearly.
Wuhan, HubeiAges 18–80 - NCT06915909Recruiting
Robotic prostate surgery with low pressure gas for less pain
This trial tests whether using lower gas pressure during robotic prostate surgery can reduce pain after the operation. It aims to help men recover more comfortably.
Stevenage, HertfordshireAges 18–75 - NCT06610825RecruitingPhase 2
Enhertu for prostate cancer resistant to hormone therapy
This trial is testing a drug called Enhertu for men whose prostate cancer has spread and is no longer responding to hormone treatments. You may join if you have a tumor sample that can be tested for a protein called HER2.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06612047Recruiting
Comparing high-field and ultra-high-field MRI for prostate cancer diagnosis
This study compares two types of MRI scans – one at 3.0 Tesla and one at 5.0 Tesla – to see which is better at finding prostate cancer. If you are scheduled for a prostate biopsy, you may be asked to get both scans to help improve detection.
Hefei, AnhuiAges 18 years+ - NCT06616155RecruitingPhase 1/Phase 2
Ruxolitinib and Enzalutamide for Resistant Prostate Cancer
This trial tests two drugs—ruxolitinib and enzalutamide—together to see if they can help men whose prostate cancer has spread and stopped responding to abiraterone. It is for those whose cancer grew quickly on abiraterone.
Chicago, IllinoisAges 18 years+ - NCT06616597RecruitingPhase 2
Targeting gut bacteria to help prostate cancer treatment work again
This trial tests whether adding metronidazole, an antibiotic, can make abiraterone work better in men with metastatic prostate cancer whose PSA is rising despite treatment. It aims to target gut bacteria that may be fueling resistance to the therapy.
Baltimore, MarylandAges 18 years+ - NCT06631521RecruitingPhase 1
Hormone pills before prostate cancer surgery
This trial tests two oral hormone drugs (darolutamide and relugolix) given before prostate removal surgery for men with high-risk prostate cancer. The goal is to see if this combination shrinks the tumor and improves treatment outcomes.
Orlando, FloridaAges 18 years+ - NCT06636526Recruiting
Testing a new prostate cancer blood test in diverse groups
This study tests a new blood test (PRODICT®) to see how well it works for finding prostate cancer in men from different ethnic backgrounds. It aims to make sure the test is accurate and fair for everyone.
Sutton, SurreyAges 40–55 - NCT06636682RecruitingPhase 2
Vaccine for men with high-risk prostate cancer after surgery
This trial tests a personalized vaccine (FK-PC101) given after prostate removal surgery for men with high-risk prostate cancer. It aims to see if the vaccine can help prevent the cancer from coming back without the need for additional hormone therapy or radiation.
Chicago, IllinoisAges Any age - NCT06652607Recruiting
PSA response as a sign of treatment success in prostate cancer
This trial is for men with prostate cancer that has spread to other parts of the body and is being treated with hormone therapy. It looks at whether a drop in PSA levels after six months can help predict how well the treatment is working.
Rome, LazioAges 18 years+ - NCT06657131Recruiting
PSMA PET scan for prostate cancer recurrence
This trial looks at how well a special PET scan (called PSMA PET) can find prostate cancer that has come back after treatment. It uses a radioactive tracer to spot cancer cells. Your doctor may already have ordered this scan as part of your regular care.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT06675357RecruitingPhase 2
FAPI PET/MRI scan for prostate cancer
This trial uses a new type of PET/MRI scan (called FAPI) to see how well it can find prostate cancer. It may help doctors learn about a different way to image the cancer. You can join if you already have a scheduled or recent PSMA PET scan.
Madison, WisconsinAges 18 years+ - NCT06684652Recruiting
Comparing targeted plus standard biopsies for prostate cancer diagnosis
This trial tests whether adding a targeted biopsy to a standard sextant biopsy improves the detection of prostate cancer. It is for men aged 45 to 85 who have a suspicious spot on an MRI of their prostate and have not had a biopsy before.
Beijing, Beijing MunicipalityAges 45–85 - NCT06687421Recruiting
Precision medicine for high-risk prostate cancer
This study aims to use precision medicine (tailored treatment based on your specific cancer) for men at high risk of prostate cancer. It may help doctors choose the best treatment for you.
UmeåAges 18 years+ - NCT06700057Recruiting
Study of lutetium treatment for prostate cancer
This study looks at patients treated with a radioactive drug called 177Lu-PSMA-617 for a type of prostate cancer that has spread, stopped responding to hormone therapy, and has been treated with chemotherapy. It checks how the treatment affects the body and the tumor using images.
BordeauxAges 18 years+ - NCT06706921RecruitingPhase 4
Predicting treatment success with PET scans in prostate cancer
This study looks at whether a special PET scan can help predict how well a targeted radiation therapy (LuPSMA) works in men with advanced prostate cancer that has spread. You would get several PET scans before and after treatment to see if the scan results can forecast your outcome.
Los Angeles, CaliforniaAges 18 years+ - NCT07686016Recruiting
Radiation therapy for prostate cancer that has spread to a few spots
This trial studies the use of radiation to the prostate and to all visible spots where cancer has spread, in men who have up to 10 small areas of spread when first diagnosed. The goal is to see if this approach can help control the cancer.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT06834152Recruiting
Online adaptive radiation for localized prostate cancer
This trial tests a new way to deliver high-precision radiation to the prostate using daily MRI or CT scans to adjust the treatment based on your exact anatomy. It aims to make radiation more accurate and reduce side effects.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06709326Recruiting
Collecting blood cells to study prostate cancer
This study uses a blood filtering procedure (apheresis) to collect prostate cancer cells from your blood for detailed analysis. It may help researchers understand why some prostate cancers spread, which could lead to better treatments. There are three groups: men with metastatic prostate cancer, men with PSA relapse after prostatectomy, and healthy volunteers.
Umeå, Norrlands University HospitalAges 18–81 - NCT06714630Recruiting
Study Learning from Men Treated for Prostate Cancer
This trial looks at long-term results after radiation therapy for prostate cancer. By studying PSA test results and imaging scans from men who were treated at least 10 years ago, researchers hope to learn more about side effects and how well the treatment worked over time.
Edinburgh, LothianAges Any age - NCT06717295Recruiting
Blood test to find cancer early and track treatment
This study uses a blood test that looks at your platelets and immune cells to find common cancers early, and for certain cancers, to monitor how well treatment is working.
RosarioAges 40–75 - NCT06733350RecruitingPhase 4
Testosterone therapy for low testosterone in men with low-risk prostate cancer
This study tests whether testosterone replacement therapy can safely improve low testosterone levels in men with low-risk prostate cancer who are not getting immediate treatment. It aims to help men feel better without worsening their cancer.
Buffalo, New YorkAges 18 years+ - NCT06737588Recruiting
Better MRI scanning for prostate cancer detection
This study tests if a special MRI measurement (ADC) can improve how well a standard MRI finds prostate cancer. If you have a suspicious MRI and are scheduled for a biopsy, this might help better understand your results.
Hefei, AnhuiAges 18 years+
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer?
- Yes. Clin2 currently lists 1,215 recruiting prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.